Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1

Interventions

Cyclophosphamide 17Etoposide 10fludarabine 9Whole-Body Irradiation 9Brentuximab Vedotin 9Melphalan 8fludarabine phosphate 7Vincristine 7Mycophenolic Acid 7Gemcitabine 7Doxorubicin 7Prednisone 6Granulocyte Colony-Stimulating Factor 6Busulfan 6Vorinostat 5Rituximab 5Peripheral Blood Stem Cell Transplantation 5Lenalidomide 5Filgrastim 5Cytarabine 5Bortezomib 5romidepsin 4pembrolizumab 4duvelisib 4Tacrolimus 4Stem Cell Transplantation 4Carmustine 4etoposide phosphate 3Sirolimus 3Dexamethasone 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma, T-Cell × Lactones × Clear all
NCT03534180 2023-10-19

Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma

City of Hope Medical Center

Phase 2 Completed
12 enrolled 8 charts
Lymphoid

Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡